About IRRAS
IRRAS is a Healthcare company based in Stockholm (Sweden) founded in 2012, and was acquired by ClearPoint Neuro in November 2025. Provider of devices for fluid control and management after surgery. IRRAS has raised $11.25 million across 2 funding rounds from investors including ClearPoint Neuro, Serendipity Innovations and Invest Stockholm. Its chief executive, as recorded, is Will Martin. IRRAS offers products and services including IRRA flow, Hummingbird Quad, Hummingbird Solo, and Hummingbird ICP Control Module. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is IRRAS AB.
Company details
IRRAS develops devices for fluid control and management for several brain pathologies, CNS therapeutic applications, and procedures. Its products include instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications. Its flagship products IRRAflow provides, dynamic control of brain fluids, for irrigation and aspiration, precise infusion of fluids and intracranial pressure monitoring. It can be used for the treatments for infections and malignant tumors such as Ventriculitis, Meningitis, Abscesses and Osteomyelitis of the skull, and others.
- Headquarters Stockholm, Sweden
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website irras.com
- Social LinkedIn X YouTube
- Acquired by ClearPoint Neuro (Nov 2025)
- Legal Name Irras Ab
- Total Equity Funding$11.25M (USD)
in 2 rounds
- Latest Funding Round$11.25M (USD), Series A
May 2016
- InvestorsClearPoint Neuro
& 2 more
- Acquired byClearPoint Neuro
(Nov 2025)
Products & Services of IRRAS
IRRAS offers a comprehensive portfolio of products and services, including IRRA flow, Hummingbird Quad, Hummingbird Solo, and Hummingbird ICP Control Module.
Provides automated irrigation and continuous pressure monitoring for drainage.
Offers quad ICP monitoring with drainage for advanced neuromonitoring.
Delivers solo ICP monitoring with accurate parenchymal measurements.
Enables rezeroing and multimodal monitoring through a single access point.
Apps and channels of IRRAS
its YouTube channel IRRAS has 440 subscribers and 30 videos.
Videos from IRRAS
The most watched videos on IRRAS's YouTube channel, IRRAS (440 subscribers). Click a video to play it here.
More on IRRAS.
Funding Insights of IRRAS
IRRAS has successfully raised a total of $11.25M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.25 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.25M
- Total Rounds 2
- Last Round Series A — $11.25M
- Investors Count 2
All 2 funding rounds of IRRAS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2016 | $11.25M | Series A | – | Serendipity Innovations | – |
| Mar 2013 | Seed | – | Invest Stockholm | – |
3 investors in total: 3 institutional.
Investors in IRRAS
IRRAS has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ClearPoint Neuro, Serendipity Innovations and Invest Stockholm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| serendipity.se | ||||
Promotes investment, business setup, and talent recruitment in Stockholm region. | 2010 | investstockholm.com | Stockholm, Sweden | |
Software and hardware solutions for MRI-guided surgical planning are provided. | 1998 | clearpointneuro.com | Irvine, United States |
Investor details for IRRAS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IRRAS
23 people are tracked at IRRAS (11 in leadership, 1 in board & advisors, 11 in team).
| Name | Role | Group |
|---|---|---|
Will Martin | CEO | Leadership |
Adam Sampson | VP of Product Excellence | Leadership |
Jeanne Warner | Vp, Clinical & Regulatory Affairs | Leadership |
John Unser | Director Of Marketing And Clinical Affairs | Leadership |
Annika Muskantor | CFO Support | Leadership |
Griffen Stapp | Chief Financial Officer | Leadership |
Anthony Butler | Marketing Director | Leadership |
Jenny Lind | Interim Head Of Group Accounting | Leadership |
Anthony Maestas | Vp, US Sales | Leadership |
Coenraad Tamse | Vice President International Sales | Leadership |
Edmond Malek | Nordic Country Head | Leadership |
Kleanthis G. Xanthopoulos | Board Member | Board & advisors |
Thomas Gogolin | International Training Manager | Team |
Jonas Gehbauer | Manager International Sales & Clinical | Team |
Samantha Obligacion | Marketing Associate | Team |
Jorge Amaya | Sr. Operations Quality Engineer | Team |
Mike Wilber | Territory Sales Manager | Team |
Celia Patricia Flores | Staff Accountant | Team |
Meredith Hoehner | Regional Sales Manager | Team |
Larissa Hauser | Clinical Application Specialist | Team |
3 more people are available in the full profile.
Complete people profiles for IRRAS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IRRAS
4 dated milestones of IRRAS across 13 years, from founding to its latest funding, stage changes and deals.
- Founded IRRAS is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $11.2M.
- Exit Acquired by ClearPoint Neuro.
Web traffic of IRRAS
The website of IRRAS (irras.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▲ 27.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Irras
Complete news archive for IRRAS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IRRAS
IRRAS was founded in 2012 and raised its 1st funding round 1 year after it was founded.
IRRAS is headquartered in Stockholm, Sweden.
Will Martin is the CEO of IRRAS, as recorded in our data.
IRRAS is a funded company, having raised a total of $11.25M across 2 funding rounds to date.
IRRAS develops devices for fluid control and management for several brain pathologies, CNS therapeutic applications, and procedures. Its products include instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications. Its flagship products IRRAflow provides, dynamic control of brain fluids, for irrigation and aspiration, precise infusion of fluids and intracranial pressure monitoring. It can be used for the treatments for infections and malignant tumors such as Ventriculitis, Meningitis, Abscesses and Osteomyelitis of the skull, and others.
IRRAS offers IRRA flow, Hummingbird Quad, Hummingbird Solo, and Hummingbird ICP Control Module.
IRRAS has 3 investors. Key investors include ClearPoint Neuro, Serendipity Innovations, and Invest Stockholm.
IRRAS operates through Irras Ab.
Yes. IRRAS was acquired by ClearPoint Neuro in November 2025.